NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

anti-CD133-PE38-KDEL fusion protein
A fusion protein consisting of an anti-single-chain variable fragment (scFv) peptide sequence targeting the extracellular domain of human CD133 (prominin-1) (anti-CD133scFV) and a deimmunized truncated form of Pseudomonas exotoxin A (38-kDa derivative of PE; PE38) where the five C-terminal amino acid residues have been replaced with the endoplasmic reticulum (ER) retention signal, KDEL, with potential antineoplastic activity. Upon administration of the anti-CD133-PE38-KDEL fusion protein, the anti-CD133 scFV moiety targets and binds to CD133, which is expressed on a variety of tumor cells. Upon internalization of the receptor-fusion protein complex, the KDEL sequence targets the fusion protein to the ER, where the PE38 exotoxin portion then inhibits protein synthesis, which results in a reduction of proliferation of CD133-expressing tumor cells. CD133, a glycoprotein expressed by a variety of cancers and especially by cancer stem cells (CSCs), plays a key role in tumor initiation, proliferation and progression. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-CD133-deimmunized pseudomonas exotoxin A-KDEL fusion protein
deimmunized CD133KDEL
deimmunized CD133KDEL toxin
Code name:CD133KDEL